Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial

Mehran Mortazavi 1 , Davood Farzin 1 , 2 , Mehran Zarhghami 1 , 3 , * , Seyed Hamzeh Hosseini 1 , 3 , Parisa Mansoori 1 and Gholamreza Nateghi 1 , 3
Authors Information
1 Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, IR Iran
2 Department of Pharmacology, School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
3 Department of Psychiatry, School of Medicine, Mazandaran University of Medical Sciences, Sari, IR Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: September 28, 2015, 9 (3); e853
  • Published Online: September 23, 2015
  • Article Type: Original Article
  • Received: June 21, 2014
  • Revised: July 24, 2014
  • Accepted: February 7, 2015
  • DOI: 10.17795/ijpbs-853

To Cite: Mortazavi M, Farzin D, Zarhghami M, Hosseini S H, Mansoori P, et al. Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial, Iran J Psychiatry Behav Sci. 2015 ; 9(3):e853. doi: 10.17795/ijpbs-853.

Abstract
Copyright © 2015, Mazandaran University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005; 15(4): 399-409[DOI][PubMed]
  • 2. Ballon J, Stroup TS. Polypharmacy for schizophrenia. Curr Opin Psychiatry. 2013; 26(2): 208-13[DOI][PubMed]
  • 3. Priebe S, Savill M, Reininghaus U, Wykes T, Bentall R, Lauber C, et al. Effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia--a multi-centre randomised controlled trial. BMC Psychiatry. 2013; 13: 26[PubMed]
  • 4. Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology. 2009; 34(5): 1322-9[DOI][PubMed]
  • 5. Saper RB, Rash R. Zinc: an essential micronutrient. Am Fam Physician. 2009; 79(9): 768-72[PubMed]
  • 6. Sayyah M, Olapour A, Saeedabad Y, Yazdan Parast R, Malayeri A. Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: a randomized placebo-controlled clinical trial. Nutrition. 2012; 28(9): 892-5[DOI][PubMed]
  • 7. Ronowska A, Dys A, Jankowska-Kulawy A, Klimaszewska-Lata J, Bielarczyk H, Romianowski P, et al. Short-term effects of zinc on acetylcholine metabolism and viability of SN56 cholinergic neuroblastoma cells. Neurochem Int. 2010; 56(1): 143-51[DOI][PubMed]
  • 8. Li Y, Zheng Y, Qian J, Chen X, Shen Z, Tao L, et al. Preventive effects of zinc against psychological stress-induced iron dyshomeostasis, erythropoiesis inhibition, and oxidative stress status in rats. Biol Trace Elem Res. 2012; 147(1-3): 285-91[DOI][PubMed]
  • 9. Mori R, Ota E, Middleton P, Tobe-Gai R, Mahomed K, Bhutta ZA. Zinc supplementation for improving pregnancy and infant outcome. Cochrane Database Syst Rev. 2012; 7[DOI][PubMed]
  • 10. Sandstead HH. Subclinical zinc deficiency impairs human brain function. J Trace Elem Med Biol. 2012; 26(2-3): 70-3[DOI][PubMed]
  • 11. Brewer GJ. Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease. Biofactors. 2012; 38(2): 107-13[DOI][PubMed]
  • 12. Ghanizadeh A, Berk M. Zinc for treating of children and adolescents with attention-deficit hyperactivity disorder: a systematic review of randomized controlled clinical trials. Eur J Clin Nutr. 2013; 67(1): 122-4[DOI][PubMed]
  • 13. Millichap JG, Yee MM. The diet factor in attention-deficit/hyperactivity disorder. Pediatrics. 2012; 129(2): 330-7[DOI][PubMed]
  • 14. Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry. 2004; 4: 9[PubMed]
  • 15. Lai J, Moxey A, Nowak G, Vashum K, Bailey K, McEvoy M. The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord. 2012; 136(1-2)-9[DOI][PubMed]
  • 16. Nikseresht S, Etebary S, Karimian M, Nabavizadeh F, Zarrindast MR, Sadeghipour HR. Acute administration of Zn, Mg, and thiamine improves postpartum depression conditions in mice. Arch Iran Med. 2012; 15(5): 306-11[PubMed]
  • 17. DeLisi LE, Fleischhacker WW. Schizophrenia today: do we know any more and can we treat it better than a decade ago? Curr Opin Psychiatry. 2008; 21(2): 131-2[DOI][PubMed]
  • 18. Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012; 73(6)-34[DOI][PubMed]
  • 19. Takeda A, Tamano H. Insight into zinc signaling from dietary zinc deficiency. Brain Res Rev. 2009; 62(1): 33-44[DOI][PubMed]
  • 20. Paoletti P, Vergnano AM, Barbour B, Casado M. Zinc at glutamatergic synapses. Neuroscience. 2009; 158(1): 126-36[DOI][PubMed]
  • 21. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007; 13(9): 1102-7[DOI][PubMed]
  • 22. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry. 2008; 165(12): 1585-93[DOI][PubMed]
  • 23. Gonzalez-Burgos G, Fish KN, Lewis DA. GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast. 2011; 2011: 723184[DOI][PubMed]
  • 24. Vazquez-Gomez E, Garcia-Colunga J. Neuronal nicotinic acetylcholine receptors are modulated by zinc. Neuropharmacology. 2009; 56(6-7): 1035-40[DOI][PubMed]
  • 25. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008; 165(8): 1040-7[DOI][PubMed]
  • 26. Lieberman JA, Javitch JA, Moore H. Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry. 2008; 165(8): 931-6[DOI][PubMed]
  • 27. Rahman A, Azad MA, Hossain I, Qusar MM, Bari W, Begum F, et al. Zinc, manganese, calcium, copper, and cadmium level in scalp hair samples of schizophrenic patients. Biol Trace Elem Res. 2009; 127(2): 102-8[DOI][PubMed]
  • 28. Farzin D, Mansouri N, Yazdani T. P. 3. a. 002 Elevated plasma copper/zinc ratios in patients with schizophrenia. Eur Neuropsychopharmacology. 2006; 16-5
  • 29. Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther. 1999; 24(5): 369-74[PubMed]
  • 30. White L, Harvey PD, Opler L, Lindenmayer JP. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology. 1997; 30(5): 263-74[PubMed]
  • 31. Bilici M, Yildirim F, Kandil S, Bekaroglu M, Yildirmis S, Deger O, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(1): 181-90[DOI][PubMed]
  • 32. Shimizu T, Kobayashi S, Tanaka M. Systemic contact dermatitis to zinc in dental fillings. Clin Exp Dermatol. 2003; 28(6): 675-6[PubMed]
  • 33. Chomette G, Auriol M, Zeitoun R, Mousques T. [Effect of the soft laser on gingival connective tissue. I--Effect on fibroblasts. Histoenzymology and electron microscopy study]. J Biol Buccale. 1987; 15(1): 45-9[PubMed]
  • 34. Morozova MA, Beniashvili AG, Lepilkina TA, Rupchev GE. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr Danub. 2012; 24(2): 159-66[PubMed]
  • 35. Safarinejad MR. The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study. BJU Int. 2010; 106(6): 840-7[PubMed]
  • 36. Rosa AO, Lin J, Calixto JB, Santos AR, Rodrigues AL. Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res. 2003; 144(1-2): 87-93[PubMed]
  • 37. Siwek M, Dudek D, Paul IA, Sowa-Kucma M, Zieba A, Popik P, et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord. 2009; 118(1-3): 187-95[DOI][PubMed]
  • 38. Paz RD, Tardito S, Atzori M, Tseng KY. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol. 2008; 18(11): 773-86[DOI][PubMed]
  • 39. de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009; 70(10): 1416-23[DOI][PubMed]
  • 40. David HN, Ansseau M, Lemaire M, Abraini JH. Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization. Biol Psychiatry. 2006; 60(1): 49-57[DOI][PubMed]
  • 41. Dold M, Li C, Gillies D, Leucht S. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol. 2013; 23(9): 1023-33[DOI][PubMed]
  • 42. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011; 69(5): 442-9[DOI][PubMed]
  • 43. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008; 165(8): 1033-9[DOI][PubMed]
  • 44. Tokdemir M, Polat SA, Acik Y, Gursu F, Cikim G, Deniz O. Blood zinc and copper concentrations in criminal and noncriminal schizophrenic men. Arch Androl. 2003; 49(5): 365-8[PubMed]
  • 45. Walsh WJ, Isaacson HR, Rehman F, Hall A. Elevated blood copper/zinc ratios in assaultive young males. Physiol Behav. 1997; 62(2): 327-9[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments